While orders of its Liquid GPS are increasing, Soon-Shiong expressed frustration with the slow pace of reimbursement and urged investor patience.
BioReference Laboratories — which is already an in-network lab with Horizon BCBS — said that the preferred lab status includes its GeneDx subsidiary.
The health insurer renewed its longstanding clinical lab services relationship with LabCorp and added Quest as an in-network provider of such services.
Questions posed by CMS about expanding PAMA data collection expose a rift between labs and other industry stakeholders over who should report lab prices.
CareFirst BlueCross BlueShield and United Health Group join six others in FDA's Private Payor Program for providing device makers presubmission feedback.
Highmark will examine the clinical and economic impact of Biocept's Target Selector liquid biopsy in patients with non-small cell lung cancer.
The partners will conduct an exploratory study to determine how the results of Exagen's lupus test impacts primary care physician practice referral patterns.
The report states that using NIPD for trisomy 21 in high-risk women could "probably reduce" the total number of invasive tests though the data is incomplete.
Myriad Genetics said this week a top-five insurer has issued a positive medical policy decision for the Prolaris prostate cancer test. Myriad, through a spokesman, declined to identify the insurer.
Cigna is the first national private payor to provider coverage for the Decipher tests, which provide a genomic assessment of tumor aggressiveness.